Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment
Autore:
Agarwala, SS; Sabbagh, MH;
Indirizzi:
Univ Pittsburgh, Inst Canc, Melanoma Ctr, Pittsburgh, PA 15213 USA Univ Pittsburgh Pittsburgh PA USA 15213 oma Ctr, Pittsburgh, PA 15213 USA
Titolo Testata:
EXPERT OPINION ON BIOLOGICAL THERAPY
fascicolo: 5, volume: 1, anno: 2001,
pagine: 869 - 879
SICI:
1471-2598(200109)1:5<869:HDIOAS>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
METASTATIC MALIGNANT-MELANOMA; ACUTE MYELOGENOUS LEUKEMIA; REACTIVE OXYGEN METABOLITES; ACUTE MYELOID-LEUKEMIA; DOSE RECOMBINANT INTERLEUKIN-2; AMERICAN JOINT COMMITTEE; CANCER STAGING SYSTEM; NATURAL-KILLER-CELLS; RANDOMIZED PHASE-III; NK CELLS;
Keywords:
acute myelogenous leukaemia; cancer immunotherapy; histamine dihydrochloride; metastatic melanoma;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
104
Recensione:
Indirizzi per estratti:
Indirizzo: Agarwala, SS Univ Pittsburgh, Inst Canc, Melanoma Ctr, 755 MUH,200 LothropSt, Pittsburgh, PA 15213 USA Univ Pittsburgh 755 MUH,200 Lothrop St Pittsburgh PA USA 15213
Citazione:
S.S. Agarwala e M.H. Sabbagh, "Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment", EXPERT OP B, 1(5), 2001, pp. 869-879

Abstract

The potential role of histamine in cancer immunotherapy has been a subjectof interest for more than a decade. A significant body of research has elucidated the action of histamine in a model system that mimics the tumour microenvironment. in vitro evidence indicates that histamine inhibits the generation and release of reactive oxygen species (ROS) by monocytes/macrophages (MO) during respiratory burst ([1]). Since ROS have been shown to abrogate peritumoural and intratumoural cytokine activation of natural killer (NK) and T-cells and induce apoptosis of these cells in vitro ([2]), inhibition of ROS may enable cytokines to activate NK and T-cells and restore their antineoplastic, cytotoxic capabilities. Experimental data indicate that histamine and interleukin-2 (IL-2) act synergistically to activate NK cell cytotoxicity (NKCC) ([3]). Although IL-2, a regulator of immune responses, hasbeen shown to promote NKCC in monotherapy for metastatic melanoma (MM), renal cell carcinoma (RCC) and acute myeloid leukaemia (AML), objective responses occur in a minority of patients and survival is not significantly extended, except for a minority of patients with MM using high-dose regimens which have not been widely adopted ([4]). In vitro findings suggest that the addition of histamine to IL-2 therapy might improve response rates and disease-free survival by protecting the cells of the immune system from oxidative stress and inducing natural endogenous immune cytotoxicity. An IL-2/histamine Phase III trial is in progress in a population of MIL patients. A recently completed Phase III trial of IL-2 vs. IL-2/histamine in patients withMM demonstrated a trend towards a superior survival benefit from IL-2/histamine for all patients entered, and a statistically significant survival benefit for patients with hepatic metastases.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 21:21:44